Cita APA

John, T., Grohé, C., Goldman, J. W., Shepherd, F. A., De Marinis, F., Kato, T., . . . Majem Tarruella, M. (2023). Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC.

Citación estilo Chicago

John, Thomas|||0000-0003-3399-5342, et al. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC. 2023.

Cita MLA

John, Thomas|||0000-0003-3399-5342, et al. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC. 2023.